JWCAR-239

N/A

Report date: 2025/06/19 20:00:08

Base Information

Drug NameJWCAR-239
Drug Alias NameJWCAR239JWCAR-239
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-lymphocyte antigen CD20 modulatorsB-lymphocyte antigen CD19 modulatorsT lymphocyte replacements
TargetsB-lymphocyte antigen CD20B-lymphocyte antigen CD19
Therapy Area/IndicationsLymphoma, Mantle-CellLymphoma, FollicularLymphoma, Large B-Cell, Diffuse +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBeijing Cancer Hospital
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Cancer Hospital
Inactive CompaniesN/A
Active IndicationsLymphoma, Mantle-CellLymphoma, FollicularLymphoma, Large B-Cell, Diffuse +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A